Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Rebecca Asher"'
Publikováno v:
Translation, Vol 11, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/930d5b1a5b9d45f1a4da05f560aa6591
Autor:
Hadia Khanani, George McClintock, Hilary Fernando, Gillian Heller, Rebecca Asher, Cindy Garcia, David P. Smith, Ian Getley, Nariman Ahmadi, Norbert Doeuk, Scott Leslie, Niruban Thanigasalam, Henry H. Woo
Publikováno v:
Société Internationale d’Urologie Journal, Vol 3, Iss 3, Pp 145-162 (2022)
Commercial airline cockpit crew (CCC) are potentially exposed to occupational risk factors that may have detrimental health effects. However, available literature on prostate cancer (PCa) as a health outcome is conflicted. Therefore, this review of c
Externí odkaz:
https://doaj.org/article/5796e312f4a547e78c588d7e1ee9f7aa
Publikováno v:
Integrative Cancer Therapies, Vol 20 (2021)
Background: Patients with cancer are often impacted by a significant symptom burden. Cancer hospitals increasingly recognize the value of complementary and integrative therapies to support the management of cancer related symptoms. The aim of this st
Externí odkaz:
https://doaj.org/article/60f50adf8e994bcebc122705758074d7
Autor:
Tamkin Ahmadzada, BE, Wendy A. Cooper, BScMed, M.B.B.S., PhD, FRCPA, Mikaela Holmes, BBiomedSc, Annabelle Mahar, M.B.B.S., FRCPA, Helen Westman, MPH, Anthony J. Gill, MD, FRCPA, Ina Nordman, M.B.B.S., FRACP, M(Med)Sc, Po Yee Yip, MbChB., FRACP, PhD, Abhijit Pal, BSc (Hons), M.B.B.S., FRACP, Rob Zielinski, FRACP, M.B.B.S., Hons, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin Epi), PhD, FRACP, Adnan Nagrial, M.B.B.S., PhD, Dariush Daneshvar, MD, FRCPA, Daniel Brungs, M.B.B.S., MMed (Clin Epi), FRCPA, Deme Karikios, BSc, M.B.B.S., FRACP, PhD, Vesna Aleksova, BMedSc, Juliet Burn, M.B.B.S., FRCPA, MIAC, Rebecca Asher, MSc, Georges E. Grau, MD, PhD, Elham Hosseini-Beheshti, MSc, PhD, Glen Reid, PhD, Stephen Clarke, MD, PhD, FRACP, Steven Kao, BHB, MbChB., PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100075- (2020)
Introduction: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could help select patients who are l
Externí odkaz:
https://doaj.org/article/8decaaa69f954183bf0aaa4a972c4d8b
Autor:
Erik van Dijk, Erik van Werkhoven, Rebecca Asher, Jennifer K. Mooi, David Espinoza, Hendrik F. van Essen, Harm van Tinteren, Nicole C. T. van Grieken, Cornelis J. A. Punt, Niall C. Tebbutt, Bauke Ylstra
Publikováno v:
van Dijk, E, van Werkhoven, E, Asher, R, Mooi, J K, Espinoza, D, van Essen, H F, van Tinteren, H, van Grieken, N C T, Punt, C J A, Tebbutt, N C & Ylstra, B 2022, ' Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer : A post hoc analysis of the randomized phase III-trial AGITG-MAX ', International Journal of Cancer, vol. 151, no. 7, pp. 1166-1174 . https://doi.org/10.1002/ijc.34061
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
The VEGF-A monoclonal antibody bevacizumab is currently recommended for first-line treatment of all metastatic colorectal cancer (mCRC) patients. Cost-benefit ratio and side-effects however necessitate patient selection. A large retrospective yet non
Autor:
Fabian Trillsch, Sven Mahner, Beyhan Ataseven, Rebecca Asher, Nanda Aryal, Coraline Dubot, Andrew Clamp, Richard T. Penson, Amit Oza, Amnon Amit, Tomasz Huzarski, Antonio Casado, Giovanni Scambia, Michael Friedlander, Nicoletta Colombo, Keiichi Fujiwara, Gabe S. Sonke, Hannelore Denys, Elizabeth S. Lowe, Chee K. Lee, Eric Pujade-Lauraine
Publikováno v:
Gynecologic Oncology. 165:40-48
Background: Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients app
Autor:
Jonathan A. Ledermann, Rebecca Asher, Michael Friedlander, Ilan Bruchim, Sarah J. Lord, Eric Pujade-Lauraine, Ronnie Shapira-Frommer, Clare L. Scott, Ursula A. Matulonis, Amit M. Oza, Philipp Harter, Charlie Gourley, Tomasz Huzarski, Val Gebski, Angelina Tjokrowidjaja, Chee Khoon Lee, Ignace Vergote, Manuel Rodrigues, Werner Meier, Tsveta Milenkova
Publikováno v:
European Journal of Cancer. 154:190-200
Background The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not r
Autor:
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, Tomasz Byrski, Patricia Pautier, Philipp Harter, Nicoletta Colombo, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Frédéric Selle, Isabelle Ray-Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Mayu Yunokawa, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Susana Banerjee, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Holger Hirte, Amnon Amit, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez De Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg
Publikováno v:
Lancet Oncology, 22, 5, pp. 620-631
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Contains fulltext : 241226.pdf (Publisher’s version ) (Closed access) BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with re
Autor:
Rebecca Asher, Sarah R Robbins, Leticia A Deveza, L. Melo, David J. Hunter, Hema Urban, Victoria L. Johnson
Publikováno v:
Arthritis Care & Research. 73:520-530
Objective To test the effectiveness of a 32-week, stepped-care intervention on disease remission rates in overweight and obese patients with medial tibiofemoral osteoarthritis (OA) compared to controls. Methods In this randomized controlled trial, el
Autor:
Pedro Ramirez, Michael Frumovitz, Rene Pareja, David Isla, Kristy Robledo, Rebecca Asher, Val Gebski, Vanessa Behan, Aldo Lopez, Reitan Ribeiro, Xiaojian Yan, Robert Coleman, Andreas Obermair
Publikováno v:
Gynecologic Oncology. 166:S53-S54